Welcome to our dedicated page for Estrella Immunopharma news (Ticker: ESLA), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma Inc (ESLA) is a clinical-stage biopharmaceutical leader advancing targeted T-cell therapies for cancer treatment. This news hub provides investors and medical professionals with essential updates on the company's pioneering ARTEMIS platform and clinical developments.
Access real-time information on ESLA's progress in immuno-oncology, including trial milestones, regulatory updates, and strategic partnerships. Our curated news collection covers critical developments in CD19/CD22-targeted therapies, research collaborations, and advancements in treating blood cancers and solid tumors.
Key focus areas include clinical trial results, scientific publications, manufacturing updates, and regulatory pathway developments. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic field.
Bookmark this page for streamlined access to ESLA's latest achievements in cellular immunotherapy. Regularly updated with official press releases and expert analysis to support informed decision-making in biopharmaceutical investments.
Estrella Immunopharma (NASDAQ: ESLA) has received a Buy rating with a $14.00 price target from CB Capital Partners, who will serve as financial advisor for their Initiation Research Report. The analysis focuses on Estrella's proprietary ARTEMIS® T-cell platform and their lead candidate EB103.
The report highlights three key aspects: 1) Superior safety and efficacy of EB103, showing high response rates without severe cytokine release syndrome or neurotoxicity syndrome; 2) Expanded patient access, particularly for high-risk non-Hodgkin lymphoma patients including those with HIV-associated and CNS lymphoma; 3) Strong strategic appeal due to the platform's innovative design and potential for expedited regulatory pathways.
Estrella Immunopharma (NASDAQ: ESLA) has successfully completed the first dose cohort in its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-Redirected ARTEMIS® T-cell therapy. The Data and Safety Monitoring Board has approved advancing to the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight.
The trial, targeting patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who failed multiple prior therapies, showed promising preliminary results. The first cohort demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events. Notably, tumor response was observed in all patients at Month 1.
The STARLIGHT-1 trial follows a standard 3+3 dose-escalation design, aiming to evaluate safety, tolerability, and preliminary efficacy of EB103 in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA) received a Buy rating with a $16.00 price target from D. Boral Capital. The analysis focuses on EB103's development in B-cell Non-Hodgkin's Lymphoma and the company's ARTEMIS® T-cell engineering platform, which mimics natural T-cell receptor mechanisms for a more regulated immune response.
The valuation model incorporates a 30% probability of success and a 30% discount rate, reflecting the early clinical development stage. EB103 is currently in Phase I/II trials for relapsed/refractory and high-risk blood cancers. The company has an engagement agreement with D. Boral Capital for investment banking services, including potential underwriting and placement agent roles.
Estrella Immunopharma (NASDAQ: ESLA) has reported a complete response in the first patient treated with EB103 CD19-Redirected ARTEMIS® T-cells in its STARLIGHT-1 Phase I/II clinical trial. The patient, diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms, achieved this response one month after treatment. Notably, no treatment-related serious adverse events were observed, despite the patient's high-risk profile.
Dr. Cheng Liu, CEO of Estrella, expressed cautious optimism about these early results, highlighting the company's goal to develop T-cell therapies that match or exceed the efficacy of current CAR-T therapies while improving safety. The STARLIGHT-1 trial aims to assess EB103's safety and determine the Recommended Phase II Dose in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA, ESLAW) has appointed Hong Zhang as Chairperson and Board member, expanding the board from five to six directors. This follows the company's recent milestone of dosing the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. Ms. Zhang brings over 25 years of financial and corporate strategy experience, having held key positions at Incinta Medical Group, Beijing Ocean Co-stone Capital Investment Management, and UOB Investment (China). CEO Dr. Cheng Liu, who previously served as Chairman, will continue as a board director.
FAQ
What is the current stock price of Estrella Immunopharma (ESLA)?
What is the market cap of Estrella Immunopharma (ESLA)?
